Signifor and Type 2 diabetes - a phase IV clinical study of FDA data

Summary:

Type 2 diabetes is reported as a side effect among people who take Signifor (pasireotide diaspartate), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Novorapid, and have Pituitary-dependent cushing's syndrome.

The phase IV clinical study analyzes which people have Type 2 diabetes when taking Signifor. It is created by eHealthMe based on reports of 886 people who have side effects when taking Signifor from the FDA, and is updated regularly.

What is Signifor?

Signifor has active ingredients of pasireotide diaspartate. eHealthMe is studying from 887 Signifor users. Check the latest studies of Signifor.

What is Type 2 diabetes?

Type 2 diabetes is found to be associated with 1,433 drugs and 2,345 conditions by eHealthMe. Check the latest studies of Type 2 diabetes.

On Jul, 16, 2026

886 people reported to have side effects when taking Signifor.
Among them, 20 people (2.26%) have Type 2 diabetes.

Among these 20 people:

How long have people been on Signifor when they have Type 2 diabetes? *

What is the gender of people who have Type 2 diabetes when taking Signifor? *

female: 100 %
male: 0.0 %

What is the age of people who have Type 2 diabetes when taking Signifor? *

What are other drugs people take besides Signifor? *

What are other side effects people have besides Type 2 diabetes? *

Gallstones (stone formation by bile component): 9 people, 45.00%
Dizziness: 7 people, 35.00%
Vision Blurred: 6 people, 30.00%
Concomitant Disease Aggravated (advanced due to some of accompanying): 6 people, 30.00%
Malaise (a feeling of general discomfort or uneasiness): 5 people, 25.00%
Tremor (trembling or shaking movements in one or more parts of your body): 5 people, 25.00%
Weight Decreased: 4 people, 20.00%
Fatigue (feeling of tiredness): 4 people, 20.00%
Electrocardiogram Qt Prolonged: 4 people, 20.00%
Dry Mouth: 4 people, 20.00%

What are the existing conditions these people have? *

Pituitary-Dependent Cushing's Syndrome (pituitary dependent hypercortisolism): 18 people, 90.00%
High Blood Pressure: 11 people, 55.00%
Heavy Or Prolong Menstrual Bleeding: 4 people, 20.00%
Osteopenia (a condition where bone mineral density is lower than normal): 4 people, 20.00%
Hypopituitarism (diminished hormone secretion by the pituitary gland, causing dwarfism in children and premature aging in adults): 4 people, 20.00%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 4 people, 20.00%
Hyperthyroidism (over activity of the thyroid gland): 4 people, 20.00%
Asthma: 4 people, 20.00%
Atopy (a genetic disposition to develop an allergic reaction): 4 people, 20.00%
Carcinoid Tumor: 4 people, 20.00%

* Approximation only. Some reports may have incomplete information.

Do you take Signifor and have Type 2 diabetes?

- Check whether Type 2 diabetes is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Signifor:

Signifor (887 reports)

Type 2 diabetes treatments and more:

Type 2 diabetes (391,582 reports)

Browse all side effects of Signifor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Type 2 diabetes:

Type 2 diabetes (1,433 drugs)

Browse all the conditions that are associated with Type 2 diabetes:

Type 2 diabetes (2,345 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pasireotide diaspartate (the active ingredients of Signifor) and Signifor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.